<DOC>
	<DOCNO>NCT00123591</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Middle East , North America . The primary objective trial evaluate safety Recombinant Activated Factor VII patient brain contusion . The secondary objective trial evaluate preliminary efficacy Recombinant Activated Factor VII prevent early haemorrhagic progression contusive brain injury .</brief_summary>
	<brief_title>Safety Preliminary Efficacy Recombinant Activated Factor VII Subjects With Traumatic Brain Injury</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Contusive brain injury ( include brain stem ) diagnose history , clinical examination confirm CT scan within 6 hour onset In British Columbia Nova Scotia , subject must = 19 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>